TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$24.64 USD
-0.65 (-2.55%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.64 +0.01 (0.02%) 4:46 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TGTX 24.64 -0.65(-2.55%)
Will TGTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TGTX
Stock Market News for Aug 7, 2024
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Other News for TGTX
Opaleye Management Inc. Increases Stake in Codexis Inc.
Interesting TGTX Put And Call Options For May 2025
New BRIUMVI? (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
New Data for BRIUMVI? (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
TG Therapeutics presents updated data from ENHANCE Phase 3b trial of BRIUMVI